Recent Posts
- FDA Okays Blood Test for Ovarian Cancer
- Replication At DNA Damage Sites Highlights Fanconi Anemia And Breast Cancer Proteins
- ASCO To Hold Annual Meeting In Chicago For The Next Ten Years: City Seen As Best Choice To Host Meeting That Continues To Grow
- Protein Partnership Leads To Pediatric Tumor Regression
- ASCO Awarded CEO Cancer Gold Standard: Achievement Underscores Organization’s Commitment To The Health And Well-Being Of Its Employees
Random Posts
- Polyomavirus Infection In Merkel Cell Carcinoma Is Associated With Better Outcomes
- Understanding A Cell's Split Personality Aids Synthetic Circuits
- New Or Not? Cracking Cyclic Natural Products For New Drugs
- Free Cancer Information CDs Now Available
- Early Ovarian Cancer Diagnosis Still Elusive (CME/CE)
- ECCO-ESMO: No Melanoma Survival Benefit with Targeted Agent (CME/CE)
- ASTRO: Statins May Boost Effects of Prostate Radiation (CME/CE)
- Charity Concerned That One Third Of Women Ignore Breast Screening Invite
- ASCO: Skin Regimen Cuts Chances of EGFR-Induced Rash (CME/CE)
- Childhood Cancer Survivors Safe to Have Kids (CME/CE)
Prescription Cancer Drugs
Toward Bold New Anti-cancer Medicines
Posted by: admin in Prescription Cancer Drugs on November 07th, 2009
Bold new strategies in the battle against cancer may turn forms of the disease that presently are incurable into manageable conditions that can be controlled for long periods of time, according to an article in the current issue of Chemical & Engineering News, ACS’ weekly newsmagazine.
C&EN Senior Editor Lisa Jarvis notes that “molecularly targeted” drugs are having a major impact in treating cancer of the breast, colon, and other body parts. Those medications interfere with specific molecules involved in cancer’s growth and spread. However, further advances are critical.
One new strategy involves cutting off cancer cells’ supply of blood sugar, or glucose, and thus starving them to death. Another uses RNA interference, a form of gene therapy in which short RNA segments serve as medication to block the genes involved in cancer. Although scientists face major hurdles in developing effective methods for administering RNA-based medicines, they are making rapid progress in doing so.
Source
Chemical & Engineering News
No Comments »
No comments yet.
RSS feed for comments on this post. TrackBack URL
Leave a comment
You must be logged in to post a comment.